| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | CT47A1 |
| Uniprot No | Q5JQC4 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-288aa |
| 氨基酸序列 | MSATGDRHPT QGDQEAPVSQ EGAQAEAAGA GNQEGGDSGP DSSDVVPAAE VVGVAGPVEG LGEEEGEQAA GLAAVPRGGS AEEDSDIGPA TEEEEEEEGN EAANFDLAVV ARRYPASGIH FVLLDMVHSL LHRLSHNDHI LIENRQLSRL MVGPHAAARN LWGNLPPLLL PQRLGAGAAA RAGEGLGLIQ EAASVPEPAV PADLAEMARE PAEEAAEEKL SEEATEEPDA EEPATEEPTA QEATAPEEVT KSQPEKWDEE AQDAAGEEEK EQEKEKDAEN KVKNSKGT |
| 预测分子量 | 30,1 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于CT47A1重组蛋白的模拟参考文献示例(注：因CT47A1研究较为小众，以下内容为虚构示例，建议通过PubMed、Google Scholar等平台查询真实文献)：
1. **文献名称**：*Expression and purification of recombinant CT47A1 protein in mammalian cells for cancer immunotherapy*
**作者**：Zhang L, et al.
**摘要**：本研究成功在HEK293细胞中表达并纯化CT47A1重组蛋白，验证其与患者血清中抗体的特异性结合，提示其作为癌症疫苗候选分子的潜力。
2. **文献名称**：*CT47A1 as a novel cancer/testis antigen: Structural characterization and clinical relevance in ovarian cancer*
**作者**：Smith J, et al.
**摘要**：通过生物信息学预测和X射线晶体学解析CT47A1重组蛋白结构，发现其在卵巢癌组织中高表达，并与患者生存率显著相关。
3. **文献名称**：*Immunogenicity assessment of recombinant CT47A1 protein in a murine model*
**作者**：Wang Y, et al.
**摘要**：在小鼠模型中评价CT47A1重组蛋白的免疫原性，证明其可诱导强烈的T细胞应答，支持其在肿瘤免疫治疗中的应用价值。
4. **文献名称**：*Proteomic screening identifies CT47A1 as a biomarker for early-stage lung adenocarcinoma*
**作者**：Chen H, et al.
**摘要**：利用重组CT47A1蛋白进行血清抗体检测，发现其在早期肺腺癌患者中特异性高表达，具有潜在诊断价值。
建议通过**PubMed**或**Web of Science**以“CT47A1 recombinant protein”为关键词检索最新真实研究。
**Background of CT47A1 Recombinant Protein**
CT47A1 (Cancer/Testis Antigen 47A1) is a member of the cancer/testis antigen (CTA) family, a group of genes predominantly expressed in germ cells of the testis but often reactivated in various cancers. CTAs are considered promising targets for immunotherapy due to their restricted normal-tissue expression and immunogenic properties in tumors. CT47A1. located on the X chromosome, is one of multiple CT47 family genes characterized by tandem repeats and conserved structural domains, suggesting potential roles in protein-protein interactions or cellular regulation.
The CT47A1 recombinant protein is engineered through molecular cloning and expression systems (e.g., *E. coli* or mammalian cells) to produce the antigen *in vitro*. This protein retains immunogenic epitopes, enabling its use in studying immune responses, antibody production, and vaccine development. In cancer biology, CT47A1 has been detected in malignancies such as lung, ovarian, and head-and-neck cancers, where its aberrant expression correlates with tumor progression and immune evasion mechanisms. Its restricted expression profile makes it a candidate for targeted therapies, including CAR-T cells or therapeutic vaccines aiming to exploit tumor-specific immunity.
Research on CT47A1 remains evolving. Challenges include understanding its precise biological function, validating its clinical relevance across cancer types, and addressing heterogeneity in tumor expression. Nonetheless, CT47A1 recombinant protein serves as a critical tool for exploring its role in oncogenesis and advancing immunotherapeutic strategies against CT47A1-positive cancers.
×
